Tandem Diabetes Care (TNDM) to Release Earnings on Wednesday

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) will likely be releasing its earnings data after the market closes on Wednesday, February 26th. Analysts expect Tandem Diabetes Care to post earnings of ($0.21) per share and revenue of $251.39 million for the quarter. Persons interested in listening to the company's earnings conference call can do so using this link.

Tandem Diabetes Care Price Performance

Shares of NASDAQ:TNDM traded down $1.12 on Friday, hitting $31.00. The stock had a trading volume of 906,169 shares, compared to its average volume of 937,531. The firm's 50 day moving average price is $35.51 and its 200-day moving average price is $36.82. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. Tandem Diabetes Care has a twelve month low of $24.42 and a twelve month high of $53.69. The company has a market capitalization of $2.04 billion, a price-to-earnings ratio of -16.06 and a beta of 1.32.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Morgan Stanley raised Tandem Diabetes Care from an "equal weight" rating to an "overweight" rating and set a $45.00 target price on the stock in a report on Monday, December 2nd. Robert W. Baird decreased their price objective on Tandem Diabetes Care from $39.00 to $37.00 and set a "neutral" rating on the stock in a research report on Thursday, November 7th. Citigroup dropped their target price on Tandem Diabetes Care from $57.00 to $50.00 and set a "buy" rating for the company in a research report on Wednesday, December 11th. Canaccord Genuity Group decreased their price target on Tandem Diabetes Care from $57.00 to $56.00 and set a "buy" rating on the stock in a report on Thursday, November 7th. Finally, Sanford C. Bernstein started coverage on shares of Tandem Diabetes Care in a research report on Wednesday, November 6th. They set an "outperform" rating and a $42.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat, Tandem Diabetes Care currently has an average rating of "Moderate Buy" and a consensus price target of $53.81.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.